Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
Highlighted with 89 tables and 90 figures, this 180-page report “Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region.
Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Recombinant Non-glycosylated Biosimilars
o Insulin
o Recombinant Human Growth Hormone (rHGH)
o Granulocyte Colony Stimulating Factor
o Interferon
• Recombinant Glycosylated Biosimilars
o Monoclonal Antibodies (mAb)
o Erythropoietin (EPO)
o Follicle Stimulating Hormone
• Recombinant Peptides and Others
o Tumor Necrosis Factor (TNF)-Inhibitor
o Parathyroid Hormone
o Enzymes, Immunomodulators, GnRH Analogs and Others
Based on Indication, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Cancer
• Autoimmune Disease
• Blood Disorder
• Diabetes
• Growth Hormone Deficiency
• Infectious Diseases
• Other Indications
Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Contract Manufacturing
• Inhouse Manufacturing
Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Hospitals and Clinics
• Research Institutes
• Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Turkey, Iran, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 26
2.2 Major Growth Drivers 28
2.3 Market Restraints and Challenges 33
2.4 Emerging Opportunities and Market Trends 36
2.5 Porter’s Fiver Forces Analysis 40
3 Segmentation of Global Market by Product Type 44
3.1 Market Overview by Product Type 44
3.2 Recombinant Non-glycosylated Biosimilars 46
3.2.1 Insulin 48
3.2.2 Recombinant Human Growth Hormone (rHGH) 49
3.2.3 Granulocyte Colony Stimulating Factor 50
3.2.4 Interferon 51
3.3 Recombinant Glycosylated Biosimilars 52
3.3.1 Monoclonal Antibodies (mAb) 53
3.3.2 Erythropoietin (EPO) 54
3.3.3 Follicle Stimulating Hormone 55
3.4 Recombinant Peptides and Others 56
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 57
3.4.2 Parathyroid Hormone 58
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 59
4 Segmentation of Global Market by Indication 60
4.1 Market Overview by Indication 60
4.2 Cancer 62
4.3 Autoimmune Disease 63
4.4 Blood Disorder 64
4.5 Diabetes 65
4.6 Growth Hormone Deficiency 66
4.7 Infectious Diseases 67
4.8 Other Indications 68
5 Segmentation of Global Market by Manufacturing 69
5.1 Market Overview by Manufacturing 69
5.2 Contract Manufacturing 71
5.3 Inhouse Manufacturing 72
6 Segmentation of Global Market by End User 73
6.1 Market Overview by End User 73
6.2 Hospitals and Clinics 75
6.3 Research Institutes 76
6.4 Other End Users 77
7 Segmentation of Global Market by Region 78
7.1 Geographic Market Overview 2019-2030 78
7.2 North America Market 2019-2030 by Country 82
7.2.1 Overview of North America Market 82
7.2.2 U.S. 86
7.2.3 Canada 96
7.2.4 Mexico 98
7.3 European Market 2019-2030 by Country 100
7.3.1 Overview of European Market 100
7.3.2 Germany 106
7.3.3 U.K. 108
7.3.4 France 110
7.3.5 Spain 112
7.3.6 Italy 114
7.3.7 Russia 116
7.3.8 Rest of European Market 118
7.4 Asia-Pacific Market 2019-2030 by Country 120
7.4.1 Overview of Asia-Pacific Market 120
7.4.2 Japan 124
7.4.3 China 127
7.4.4 Australia 129
7.4.5 India 131
7.4.6 South Korea 133
7.4.7 Rest of APAC Region 135
7.5 South America Market 2019-2030 by Country 137
7.5.1 Argentina 140
7.5.2 Brazil 142
7.5.3 Chile 144
7.5.4 Rest of South America Market 146
7.6 MEA Market 2019-2030 by Country 147
7.6.1 Turkey 150
7.6.2 Iran 152
7.6.3 South Africa 154
7.6.4 Other National Markets 156
8 Competitive Landscape 157
8.1 Overview of Key Vendors 157
8.2 New Product Launch, Partnership, Investment, and M&A 161
8.3 Company Profiles 162
AMEGA Biotech S.A. 162
Apotex Inc. 164
Biocon Ltd 165
Biogen Inc. 166
Boehringer Ingelheim 167
Celltrion, Inc. 168
Dr. Reddy’s Laboratories Ltd. 169
Eli Lilly and Company 170
Intas Pharmaceuticals Ltd. 171
LG Chem, Ltd. 172
Merck and Co. Inc. 173
Mylan N.V. 174
Pfizer Inc. 175
Samsung Biologics Co., Ltd. 176
Sandoz International GmbH 177
STADA Arzneimittel AG 178
Teva Pharmaceutical Industries Ltd. 179
RELATED REPORTS 180
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Ěý
Ěý
*If Applicable.
